Viewing Study NCT04431635


Ignite Creation Date: 2025-12-24 @ 10:10 PM
Ignite Modification Date: 2026-01-01 @ 1:39 AM
Study NCT ID: NCT04431635
Status: TERMINATED
Last Update Posted: 2024-09-27
First Post: 2020-06-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Sponsor: University of Michigan Rogel Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module